Suzhou Genhouse Bio Co., Ltd.

Privately held: no public share price

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 2
SHP2Small molecule
Non-Small Cell Lung Cancer

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
GH21Phase 2Locally Advanced or Metastatic Solid Tumors
Est. primary completion 2026-12-30 · NCT07318649 · CT.gov ↗
What to watch
2027 (1)
September 2027 (1)
GH21Phase 1/2Locally Advanced or Metastatic Solid Tumors Harboring KRAS G12C Mutation
Est. primary completion 2027-09-30 · NCT06435455 · CT.gov ↗
What to watch
2029 (1)
October 2029 (1)
GH21Phase 1/2Advanced Solid Tumor Cancer
Est. primary completion 2029-10-30 · NCT07446725 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.